Member Info for Brysoa

Do we know for sure that the intention is to publish the inpatient results in advance of the home delivery arm of the study? I must check but I have a vague recollection that they are rolled up into one study and, if so, it is possible that there is no process under way to publish as yet. Of course that does not mean to say that the data from the hospital patients can’t be the subject of serious discussions with regulators.

Normally, peer reviewers are chosen by the journal to which a scientific paper is submitted for publication. Their remit is to check for scientific validity an confirm whether fit for publication. Publication, therefore, represents something of a scientific seal of approval - confirming no flaws in the study methodology, statistical analysis, etc. Reviewers are chosen from the relevant field of study and are acknowledged academic experts.

Looking at the “recent trades” just appearing now on the lse board, these date back as far as Tuesday and are all very significant buys. A lot has been going on under the radar.

Not so much late trades as late reported trades. These trades seem to have taken place “under the radar” throughout the day. This explains the long stretches of sell, sell, sell trades reported as the day went on. Is this a ploy? Asking for a friend.

Scientific report from June confirming in-vitro activity of Interferon beta 1a (active element of SNG001) against SARS-Cov2. Old news, I know, but consistent with subsequent events.
https://academic.oup.com/jid/article/doi/10.1093/infdis/jiaa350/5860074

... source National Institutes for Health, July 2020

Some nervousness about generic nebulised Interferon Alfa out there. But:

“Interferon Alfa-2b Treatment for COVID-19
This study has not been peer reviewed.

In a retrospective cohort study of 77 adults with moderate COVID-19 in China, participants were treated with nebulized interferon alfa-2b, nebulized interferon alfa-2b with umifenovir (not available in the United States), or umifenovir only. The time to viral clearance in the upper respiratory tract and reduction in systemic inflammation was faster in the interferon alfa-2b groups than in the umifenovir only group. However, the results of this study are difficult to interpret because participants in the interferon alfa-2b with umifenovir group were substantially younger than those in the umifenovir only group (mean age 40 years vs. 65 years) and had fewer comorbidities (15% vs. 54%) at study entry. The nebulized interferon alfa-2b formulation is not approved by the Food and Drug Administration for use in the United States.2“

Also, beta less prone to side effects than Alfa.

Thank you for a thoughtful and objective opinion, with which I generally agree despite the fact that it is 51 years since I was a medical student! The data speak for themselves; ditto the statistical analyses. The only reservation I have relates to the randomisation to the study and control groups. By chance it turns out that there are excesses of diabetic, cardiovascular and BAME subjects in the control group compared to the study group. ThIS can happen with randomisation. IT doesn’t invalidate the results as reported but could give regulators the basis to ask for more work. Against this is the pressing need for solutions to a global problem. Overall I think that this is a realLy promising prospect and the material looks to be safe but there may be some caution on the part of regulators to be overcome..

Someone asked about IP protection a while ago. These relate to US and Europe:
https://www.ipgroupplc.com/media/portfolio-news/2009/2009-09-04b
and
https://www.ipgroupplc.com/media/portfolio-news/2010/2010-05-06

Oops, I meant 1.15m share sells.

2 identical 1.5m share “sells” within a couple of trading hours. Meaning?

https://www.lamellar.com/uploads/images/pdf%20files/Combatting%20the%20long-term%20spectre%20of%20COVID-19%3A%20LAMELLASOME%20as%20a%20therapeutic%20approach%20to%20complement%20antivirals%20and%20immunisation.pdf

ClimbingWooster. Market taking its lead from the Dow where reality is kicking in: the fat lady hasn’t sung yet In the coronavirus opera.